{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:29:51Z","timestamp":1790713791245,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ymgme.2023.107527","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T22:30:53Z","timestamp":1674685853000},"page":"107527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1"],"prefix":"10.1016","volume":"138","author":[{"given":"M. Judith","family":"Peterschmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith C.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allena J.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne B.","family":"Zajdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.107527_bb0005","series-title":"OMMBID: The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher disease","author":"Grabowski","year":"2013"},{"issue":"6","key":"10.1016\/j.ymgme.2023.107527_bb0010","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"issue":"16","key":"10.1016\/j.ymgme.2023.107527_bb0015","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107527_bb0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbalip.2007.11.004","article-title":"Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention","volume":"1781","author":"Groener","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.ymgme.2023.107527_bb0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ymgme.2018.02.004","article-title":"Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - a statistical insight","volume":"123","author":"Tylki-Szymanska","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107527_bb0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF02436762","article-title":"Elevated plasma chitotriosidase activity in various lysosomal storage disorders","volume":"18","author":"Guo","year":"1995","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107527_bb0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1023\/B:BOLI.0000043025.17721.fc","article-title":"The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update","volume":"27","author":"Michelakakis","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107527_bb0040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/01.ATV.19.3.687","article-title":"Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages","volume":"19","author":"Boot","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107527_bb0045","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/humu.20524","article-title":"Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring","volume":"28","author":"Grace","year":"2007","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107527_bb0050","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10038-006-0086-1","article-title":"Human CHIT1 gene distribution: new data from Mediterranean and European populations","volume":"52","author":"Piras","year":"2007","journal-title":"J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107527_bb0055","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/jhg.2014.16","article-title":"Allele frequency of a 24 bp duplication in exon 10 of the CHIT1 gene in the general Korean population and in Korean patients with Gaucher disease","volume":"59","author":"Woo","year":"2014","journal-title":"J. Hum. Genet."},{"issue":"447","key":"10.1016\/j.ymgme.2023.107527_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1651-2227.2005.tb02110.x","article-title":"Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases","volume":"94","author":"Aerts","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107527_bb0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13643-017-0483-x","article-title":"Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data","volume":"6","author":"Raskovalova","year":"2017","journal-title":"Syst Rev"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107527_bb0070","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2019.236083","article-title":"Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data","volume":"106","author":"Raskovalova","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.ymgme.2023.107527_bb0075","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"19","key":"10.1016\/j.ymgme.2023.107527_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197159","article-title":"Value of Glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review","volume":"21","author":"Revel-Vilk","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107527_bb0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2020.01.009","article-title":"Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy","volume":"129","author":"Nair","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107527_bb0090","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical pharmacogenetics implementation. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2023.107527_bb0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcmd.2017.01.006","article-title":"A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration","volume":"68","author":"Peterschmitt","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107527_bb0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1","volume":"14","author":"Peterschmitt","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.ymgme.2023.107527_bb0105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ymgme.2023.107527_bb0110","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107527_bb0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107527_bb0120","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107527_bb0125","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107527_bb0130","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ajh.26276","article-title":"Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: phase 3 ENGAGE trial final results","volume":"96","author":"Mistry","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.ymgme.2023.107527_bb0135","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood"},{"issue":"9985","key":"10.1016\/j.ymgme.2023.107527_bb0140","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107527_bb0145","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jimd.12192","article-title":"Expanding the clinical utility of glucosylsphingosine for Gaucher disease","volume":"43","author":"Saville","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107527_bb0150","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107527_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079732","article-title":"Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients","volume":"8","author":"Rolfs","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ymgme.2023.107527_bb0160","doi-asserted-by":"crossref","first-page":"E140","DOI":"10.1002\/ajh.25074","article-title":"Glucosylsphingosine is a reliable response biomarker in Gaucher disease","volume":"93","author":"Arkadir","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107527_bb0165","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1515\/cclm-2019-0949","article-title":"LC-MS\/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population","volume":"58","author":"Irun","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ymgme.2023.107527_bb0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clinbiochem.2020.10.011","article-title":"Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS\/MS","volume":"87","author":"Tang","year":"2021","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgme.2023.107527_bb0175","author":"Food and Drug Administration, National Institutes of Health"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107527_bb0180","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"issue":"12","key":"10.1016\/j.ymgme.2023.107527_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114669","article-title":"Plasma lysosphingomyelin demonstrates great potential as a diagnostic biomarker for Niemann-pick disease type C in a retrospective study","volume":"9","author":"Welford","year":"2014","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.ymgme.2023.107527_bb0190","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1016\/j.cell.2021.08.002","article-title":"Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic","volume":"184","author":"Logan","year":"2021","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ymgme.2023.107527_bb0195","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"on behalf of the Human Genome Variation Society (HGVS), the Human Variome Project (HVP), and the Human Genome Organisation (HUGO). HGVS Recommendations for the Description of Sequence Variants: 2016 Update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum. Mutat."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223001579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223001579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T01:40:12Z","timestamp":1703295612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223001579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1096719223001579"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107527","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107527"}}